Insiders who reported open-market trades in the last 12 months at the companies Serge Saxonov files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Adam Taich - $4.84M in TXG purchases and sales in the last 12 months
John R. Stuelpnagel - $2.39M in TXG purchases and sales in the last 12 months
Benjamin J. Hindson - $1.46M in TXG purchases and sales in the last 12 months
Shehnaaz Suliman - $792K in TXG purchases and sales in the last 12 months
Sarah A. Teichmann - $579K in TXG purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Serge Saxonov is a corporate insider, tracked as Chief Executive Officer, Director of 10x Genomics, Inc. (TXG). InsiderAlpha holds 19 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Serge Saxonov submitted recently?
5 primary Form 4 filings in the last 90 days, covering 1 company.
Has Serge Saxonov been buying or selling stock?
Recorded transactions: 0 open-market purchases and 24 open-market sales ($7.04M) across all tracked filings.
Serge Saxonov is Chief Executive Officer, Director of 10x Genomics, Inc. (TXG). 19 SEC Form 4 filings on record going back to 2024, most recently on 24 September 2026. Most recent open-market trade: sold $231K of TXG on 24 September 2026. Lifetime open-market sales: $7.04M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Serge Saxonov.
InsiderAlpha's records for Serge Saxonov go back to 2024: 19 primary Form 4 filings, an average of 6.3 per year. 20 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
